HAPLN1 and osteoarthritis: Regarding cohort and retrospective observational studies, assessed using the ROBINS-I tool, included works such as that of Seung-Min Na et al. (2020) [27], which compared the use of BMAC and Cartistem in patients with osteoarthritis, and Hu Liu et al. (2023) [28], focused on the analysis of HAPLN1 expression in osteogenic differentiation(see Table 4).